Vujnic Milorad, Peric Stojan, Calic Zeljka, Benovic Natasa, Nisic Tanja, Pesovic Jovan, Savic-Pavicevic Dusanka, Rakocevic-Stojanovic Vidosava
Faculty of Medicine, University of Banja Luka, Banja Luka, Republic of Srpska, Bosnia and Herzegovina, Serbia.
Neurology Clinic, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Serbia.
Acta Myol. 2018 Dec 1;37(4):252-256. eCollection 2018 Dec.
metabolic syndrome (MetS) increases risk of cardiovascular diseases and diabetes mellitus type 2. Aim of this study was to investigate frequency and features of MetS in a large cohort of patients with DM2.
MATERIALS & METHODS: this cross-sectional study included 47 DM2 patients. Patients were matched with 94 healthy controls (HCs) for gender and age. MetS was diagnosed according to the new worldwide consensus criteria from 2009.
mean age of DM2 patients was 52 ± 11 years, 15 (32%) were males, and mean disease duration was 15 ± 14 years. MetS was present in 53% of DM2 patients and 46% of HCs (p > 0.05). All components of the MetS appeared with the similar frequency in DM2 and HCs, respectively: hypertension 64 52%, central obesity 62 74%, hypertriglyceridemia 49 39%, hyperglycemia 42 33% and low HDL cholesterol 30 42% (p > 0.05). DM2 patients were more commonly on lipid lowering therapy compared to HCs (12 3%, p = 0.05). Fifteen (32%) patients with DM2 and only one (1%) subject from control group had diabetes mellitus (p < 0.01). Insulin resistance was found in thirty (65%) patients with DM2. Presence of MetS was not associated with patient's gender, age, severity nor duration of the disease (p > 0.05).
more than half of DM2 subjects met the criteria for the MetS. We suppose that treatment of metabolic disturbances may reduce cardiovascular complications and improve quality of life in patients with DM2, which is progressive and still incurable disorder.
代谢综合征（MetS）会增加心血管疾病和2型糖尿病的风险。本研究的目的是调查一大群2型糖尿病（DM2）患者中MetS的发生率和特征。
这项横断面研究纳入了47例DM2患者。根据性别和年龄将患者与94名健康对照者（HCs）进行匹配。根据2009年新的全球共识标准诊断MetS。
DM2患者的平均年龄为52±11岁，男性15例（32%），平均病程为15±14年。53%的DM2患者和46%的HCs存在MetS（p>0.05）。MetS的所有组分在DM2患者和HCs中分别以相似的频率出现：高血压64%对52%，中心性肥胖62%对74%，高甘油三酯血症49%对39%，高血糖42%对33%，低高密度脂蛋白胆固醇30%对42%（p>0.05）。与HCs相比，DM2患者更常接受降脂治疗（12%对3%，p=0.05）。15例（32%）DM2患者和对照组中仅1例（1%）受试者患有糖尿病（p<0.01）。在30例（65%）DM2患者中发现胰岛素抵抗。MetS的存在与患者的性别、年龄、疾病严重程度或病程无关（p>0.05）。
超过一半的DM2患者符合MetS标准。我们认为，代谢紊乱的治疗可能会减少DM2患者的心血管并发症并改善其生活质量，DM2是一种进行性且仍无法治愈的疾病。
